New hope for tough leukemia: drug combo shows promise in early trial
NCT ID NCT03808610
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at adding a targeted drug called venetoclax to low-intensity chemotherapy for adults with acute lymphoblastic leukemia (ALL) that came back or didn't respond to treatment. The goal was to find the safest dose and see if the combination could help control the disease. The trial was stopped early, but the results help guide future research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells outsmart resistant blood cancers?
- Triple-Target CAR T-Cells offer new hope for tough blood cancers
- New drug cocktail shows promise for Hard-to-Treat leukemia
- Can a pill make CAR T-Cell therapy last longer?
- Smart drug hunts down hidden leukemia cells
- New cocktail of cancer drugs shows promise in early leukemia trial